Impacts of Matrix Metalloproteinase-2 Promoter Genotypes on Breast Cancer Risk.

IF 2.6 4区医学 Q2 GENETICS & HEREDITY

Cancer Genomics & Proteomics Pub Date : 2024-09-01 DOI:10.21873/cgp.20467

Chih-Chiang Hung, Chung-Lin Tsai, Yu-Ting Chin, Yun-Chi Wang, Chia-Hua Liu, Meng-Liang Lin, Shih-Shun Chen, Jie-Long He, Chia-Wen Tsai, Chen-Hsien Su, DA-Tian Bau, Wen-Shin Chang

{"title":"Impacts of Matrix Metalloproteinase-2 Promoter Genotypes on Breast Cancer Risk.","authors":"Chih-Chiang Hung, Chung-Lin Tsai, Yu-Ting Chin, Yun-Chi Wang, Chia-Hua Liu, Meng-Liang Lin, Shih-Shun Chen, Jie-Long He, Chia-Wen Tsai, Chen-Hsien Su, DA-Tian Bau, Wen-Shin Chang","doi":"10.21873/cgp.20467","DOIUrl":null,"url":null,"abstract":"Background/aim: Matrix metalloproteinase-2 (MMP-2) has been implicated in the pathogenesis of breast cancer (BC). However, there is limited research on the role of MMP-2 genotypes in BC risk. This study aimed to investigate the associations between two MMP-2 promoter polymorphisms, rs243865 and rs2285053, and BC risk.Materials and methods: MMP-2 genotypes were analyzed using PCR-based RFLP methodology in a cohort comprising 1,232 BC cases and 1,232 controls.Results: Genotypic frequencies of MMP-2 rs243865 and rs2285053 in controls were consistent with Hardy-Weinberg equilibrium (p=0.3702 and 0.2036, respectively). There were no significant differences in the distribution of rs243865 and rs2285053 genotypes between BC cases and controls (p for trend=0.1602 and 0.2170, respectively). Variant genotypes at rs243865 and rs2285053 appeared to confer a protective effect, although not statistically significant (all p>0.05). Similarly, the variant T allele at rs243865 and rs2285053 showed a non-significant trend towards decreased BC risk (OR=0.84 and 0.89, 95%CI=0.69-1.02 and 0.78-1.02, p=0.0811 and 0.1043, respectively). There was no interaction observed between MMP-2 rs243865 or rs2285053 genotypes and age. Stratified analysis did not reveal significant associations between MMP-2 rs243865 or rs2285053 genotypes and triple-negative breast cancer (TNBC) (p=0.6458 and 0.8745, respectively). Among both TNBC and non-TNBC cases, none of the variant genotypes at rs243865 or rs2285053 showed significant associations with TNBC (all p>0.05).Conclusion: MMP-2 rs243865 and rs2285053 genotypes appear to have a minimal impact on individual susceptibility to BC or TNBC.","PeriodicalId":9516,"journal":{"name":"Cancer Genomics & Proteomics","volume":null,"pages":null},"PeriodicalIF":2.6000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11363925/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Genomics & Proteomics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/cgp.20467","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}

引用次数: 0

Abstract

Background/aim: Matrix metalloproteinase-2 (MMP-2) has been implicated in the pathogenesis of breast cancer (BC). However, there is limited research on the role of MMP-2 genotypes in BC risk. This study aimed to investigate the associations between two MMP-2 promoter polymorphisms, rs243865 and rs2285053, and BC risk.

Materials and methods: MMP-2 genotypes were analyzed using PCR-based RFLP methodology in a cohort comprising 1,232 BC cases and 1,232 controls.

Results: Genotypic frequencies of MMP-2 rs243865 and rs2285053 in controls were consistent with Hardy-Weinberg equilibrium (p=0.3702 and 0.2036, respectively). There were no significant differences in the distribution of rs243865 and rs2285053 genotypes between BC cases and controls (p for trend=0.1602 and 0.2170, respectively). Variant genotypes at rs243865 and rs2285053 appeared to confer a protective effect, although not statistically significant (all p>0.05). Similarly, the variant T allele at rs243865 and rs2285053 showed a non-significant trend towards decreased BC risk (OR=0.84 and 0.89, 95%CI=0.69-1.02 and 0.78-1.02, p=0.0811 and 0.1043, respectively). There was no interaction observed between MMP-2 rs243865 or rs2285053 genotypes and age. Stratified analysis did not reveal significant associations between MMP-2 rs243865 or rs2285053 genotypes and triple-negative breast cancer (TNBC) (p=0.6458 and 0.8745, respectively). Among both TNBC and non-TNBC cases, none of the variant genotypes at rs243865 or rs2285053 showed significant associations with TNBC (all p>0.05).

Conclusion: MMP-2 rs243865 and rs2285053 genotypes appear to have a minimal impact on individual susceptibility to BC or TNBC.

查看原文本刊更多论文

基质金属蛋白酶-2 启动子基因型对乳腺癌风险的影响

背景/目的：基质金属蛋白酶-2（MMP-2）与乳腺癌（BC）的发病机制有关。然而，有关 MMP-2 基因型在乳腺癌风险中的作用的研究十分有限。本研究旨在调查两个MMP-2启动子多态性（rs243865和rs2285053）与乳腺癌风险之间的关系：在由1232例BC病例和1232例对照组成的队列中，采用基于PCR的RFLP方法分析了MMP-2基因型：结果：对照组中MMP-2 rs243865和rs2285053的基因型频率与Hardy-Weinberg平衡一致（p分别为0.3702和0.2036）。在 BC 病例和对照组之间，rs243865 和 rs2285053 基因型的分布无明显差异（趋势 p 分别为 0.1602 和 0.2170）。rs243865和rs2285053的变异基因型似乎具有保护作用，但无统计学意义（均为p>0.05）。同样，rs243865 和 rs2285053 的变异 T 等位基因也显示出 BC 风险下降的非显著趋势（OR=0.84 和 0.89，95%CI=0.69-1.02 和 0.78-1.02，p=0.0811 和 0.1043）。在 MMP-2 rs243865 或 rs2285053 基因型与年龄之间没有观察到交互作用。分层分析未发现 MMP-2 rs243865 或 rs2285053 基因型与三阴性乳腺癌（TNBC）之间存在显著关联（p=0.6458 和 0.8745）。在TNBC和非TNBC病例中，rs243865或rs2285053的变异基因型与TNBC均无显著相关性（均为p>0.05）：结论：MMP-2 rs243865和rs2285053基因型似乎对 BC或TNBC的个体易感性影响很小。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Genomics & Proteomics ONCOLOGY-GENETICS & HEREDITY

CiteScore

5.00

自引率

8.00%

发文量

期刊介绍： Cancer Genomics & Proteomics (CGP) is an international peer-reviewed journal designed to publish rapidly high quality articles and reviews on the application of genomic and proteomic technology to basic, experimental and clinical cancer research. In this site you may find information concerning the editorial board, editorial policy, issue contents, subscriptions, submission of manuscripts and advertising. The first issue of CGP circulated in January 2004. Cancer Genomics & Proteomics is a journal of the International Institute of Anticancer Research. From January 2013 CGP is converted to an online-only open access journal. Cancer Genomics & Proteomics supports (a) the aims and the research projects of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH and (b) the organization of the INTERNATIONAL CONFERENCES OF ANTICANCER RESEARCH.